drugset
drugset / Trial / NCT00455559

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

NCT00455559 ↗

Phase 2 Completed 40 enrolled AEterna Zentaris M.D. Anderson Cancer Center · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II trial designed to determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.

Timeline

Start
2006-08
Primary completion
2010-11
Completion
2011-10

Publications

  • Results Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: 10563

Drugs

EvaluationDrugModalityDoseRoute
Subject Perifosine Small molecule 100 mg Oral
Subject Perifosine Small molecule 900 mg Oral
Background Imatinib Small molecule — Oral

Indications

gastrointestinal stromal tumor